Insmed (NASDAQ:INSM) Given New $231.00 Price Target at TD Cowen

Insmed (NASDAQ:INSM) had its price target boosted by equities research analysts at TD Cowen from $223.00 to $231.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price objective would indicate a potential upside of 11.67% from the stock’s current price.

A number of other research analysts have also weighed in on the stock. Truist Financial boosted their target price on shares of Insmed from $126.00 to $139.00 and gave the stock a “buy” rating in a research report on Thursday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Wednesday, October 8th. Cantor Fitzgerald began coverage on Insmed in a report on Tuesday, October 28th. They issued an “overweight” rating and a $192.00 target price on the stock. Jefferies Financial Group lifted their price target on Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, August 13th. Finally, Bank of America raised their price objective on shares of Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Nineteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and a consensus target price of $175.53.

Insmed Trading Up 1.6%

Shares of INSM stock traded up $3.30 during trading hours on Thursday, reaching $206.86. 420,709 shares of the stock traded hands, compared to its average volume of 2,625,320. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $44.12 billion, a PE ratio of -36.19 and a beta of 1.05. Insmed has a 1-year low of $60.40 and a 1-year high of $208.00. The business has a fifty day moving average price of $165.61 and a 200 day moving average price of $123.38.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Insmed will post -4.56 EPS for the current year.

Insider Activity

In other news, Director Melvin Md Sharoky sold 10,000 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director owned 262,675 shares in the company, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Leo Lee sold 75,000 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the sale, the director owned 54,677 shares of the company’s stock, valued at $10,711,224.30. This trade represents a 57.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 252,922 shares of company stock valued at $43,533,383. 3.00% of the stock is owned by company insiders.

Institutional Trading of Insmed

Several large investors have recently made changes to their positions in the business. Kingsview Wealth Management LLC raised its holdings in shares of Insmed by 2.7% in the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 60 shares during the last quarter. Choreo LLC raised its position in Insmed by 2.9% in the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 65 shares during the last quarter. Spire Wealth Management raised its position in shares of Insmed by 11.5% during the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 80 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Insmed by 59.6% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 81 shares during the period. Finally, Moody Aldrich Partners LLC boosted its holdings in Insmed by 2.4% in the third quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock valued at $799,000 after acquiring an additional 132 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.